Background
==========

Recent advances in preoperative evaluation, treatment strategies and rectal cancer modalities have lead to better survival outcomes for patients with rectal cancer and a lower incidence of local recurrence \[[@B1],[@B2]\]. Despite such improvements, 6-10% of patients with primary rectal cancer still experience intrapelvic local recurrence with or without distant metastasis \[[@B3]-[@B5]\]. These patients show a poor survival outcome with a nearly zero 5-year survival and 3-12 months of median survival when treated by only supportive care or palliative treatment \[[@B4]\]. Moreover, troublesome symptoms related to local recurrence reduce the quality of life during surviving periods. Recent studies have reported that radical surgery with microscopic curative resection presents a 48-60% long-term survival rate in patients surviving at 5 years \[[@B3],[@B4],[@B6]-[@B9]\]. These observations suggest that local control of LRRC is significantly associated with long-term survival and that the first goal of LRRC treatment should be local tumor control \[[@B5]\].

However, an aggressive approach with surgery alone also has severe weaknesses in that curative surgery is possible for only 20-30% of patients with locally recurrent rectal cancer (LRRC), because the intrapelvic space is too narrow to perform an R0 resection, and previous treatments, including surgery and radiotherapy, induce extensive fibrosis \[[@B3],[@B4]\]. Moreover, high post-operative morbidities, of 30-60% \[[@B6]-[@B8]\], and the non-operable state of some patients should also be considered in the clinical situation. To compensate for the shortage of radical surgery, chemoradiotherapy (CRT) with adjuvant or curative intent has a definitive role in improving the clinical outcome of patients with LRRC. Some studies have demonstrated that multimodal treatment including CRT results in better clinical outcomes, but the role and strategies for CRT have not yet been established. Thus, the purpose of the present study was to assess the clinical outcomes of CRT with or without surgery for patients with LRRC and to find useful and significant prognostic factors for the clinical situation.

Methods
=======

Patients
--------

This study was performed in accordance with the guidelines of our institutional review board. All patients provided written informed consent before salvage treatment.

Between January 2001 and February 2009, 67 patients with LRRC underwent CRT with or without surgery as a salvage treatment at the National Cancer Center (Goyang, Korea). Inclusion criteria were: *(1)*histologically confirmed primary rectal adenocarcinoma, *(2)*recurrent sites confined to the pelvic cavity, *(3)*no evidence of distant metastasis, and *(4)*salvage treatment with a curative aim.

Patient characteristics are shown in Table [1](#T1){ref-type="table"}. The recurrence-free interval from the initial treatment of the primary tumor to locoregional recurrence ranged from 3 to 206 months (median, 22 months). Of 67 patients, 45 (67.2%) presented with local recurrence after a sphincter-saving radical surgery to remove a primary tumor, 17 patients (25.4%) developed recurrence following an abdominoperineal resection, and five patients (7.5%) experienced recurrence following local excision. Fifty-five patients (82.1%) had a history of adjuvant chemotherapy for a primary tumor, and 23 (34.3%) received adjuvant radiotherapy for a primary tumor. Symptoms related to local recurrence were sciatic pain in 17 patients, bowel habit changes in two patients, and a ureteral obstruction in one patient.

###### 

Patient and treatment characteristics

  Characteristics                     Value (%)
  ----------------------------------- --------------------
  Median age, years (range)           57 (30-84)
  Gender                              
   Male                               40 (59.7)
   Female                             27 (40.3)
  Stage at initial diagnosis          
   ypStage 0                          3 (4.2)
   pStage I/ypStage I                 5 (7.0)/1 (1.4)
   pStage II/ypStage II               14 (19.7)/3 (4.2)
   pStage III/ypStage III             21 (29.6)/8 (11.3)
   pStage IV/ypStage IV               6 (8.5)/1 (1.4)
   pT1-2Nx                            5 (7.0)
  Recurrence history                  
   0                                  51 (76.1)
   1                                  16 (23.9)
  Symptoms at recurrence              
   Yes                                20 (29.9)
   No                                 47 (70.1)
  Recurrent site                      
   Central                            21 (31.3)
   Lateral                            30 (44.8)
   Posterior                          16 (23.9)
  Pretreatment CEA                    
   Normal (≤ 5 ng/mL)                 37 (55.2)
   High (\> 5 ng/mL)                  30 (44.8)
  Salvage treatment                   
   Surgery + CRT                      45 (67.2)
   CRT alone                          22 (32.8)
  Chemotherapy regimen                
   Fluoropyrimidine-alone             35 (52.2)
   Irinotecan or Oxaliplatin-based    31 (46.3)
   No                                 1 (1.5)
  Radicality of resection             
   R0                                 19 (28.4)
   R1                                 24 (35.8)
   R2                                 2 (4.0)
   No surgery                         22 (32.8)
  Median radiation dose, Gy (range)   57.2 (44.3-74.4)

Values in parentheses are percentages unless indicated otherwise. CRT, chemoradiotherapy; R0, microscopically radical; R1, microscopically irradical; R2, macroscopically irradical; Gy, Gray; CEA, carcinoembryonic antigen.

Through biopsy or surgical resection, 45 patients were confirmed histologically to have developed a local recurrence. In 22 patients, radiological evidence, including a positive positron-emission tomography (PET) scan or serial radiological examinations that showed progressive growth of the mass, were considered sufficient evidence to diagnose a local recurrence \[[@B10],[@B11]\]. All patients were evaluated by digital rectal examination, a complete blood count, a liver function test, carcinoembryonic antigen (CEA) level, computed tomography (CT) of the chest and abdomino-pelvis, whole body PET, and magnetic resonance imaging (MRI) of the pelvis.

Treatment
---------

Following the diagnosis of a locoregional recurrence, a surgeon, a medical oncologist, and a radiation oncologist reviewed the results of the diagnostic work-up to determine which treatment modality would be best suited for each patient. Considered unsuitable for curative surgery, 22 patients among 67 patients received definitive CRT without surgery. The other 45 underwent resection of a locally recurrent lesion with curative intent and preoperative (n = 3) or postoperative CRT (n = 42). Most adjuvant RT approaches consisted of post-operative, rather than pre-operative, as following reasons. *(1)*If a diagnosis is uncertain, histological confirm was possible through surgery. *(2)*If a patient has limitations for RT, such as previous RT history or small bowel adhesion at recurrence site, we performed omental flap transposition \[[@B12]\]. It functioned as spacer to increase a distance between small bowel and RT target area. *(3)*If RT target area and rectum are too close, we could perform protective colostomy for the prevention of RT-induced proctitis. *(4)*In some cases, preferences of doctor and patient were cause of such practice.

Radiotherapy was administered using three-dimensional conformal radiation (*n*= 60), proton beam therapy (*n*= 4), or helical tomotherapy (*n*= 3). All patients underwent a CT simulation in the treatment position, which was generally prone. The gross tumor volume, consisting of all detectable tumors, was determined from the CT, PET, and MRI data. The clinical target volume covered the gross tumor volume, tumor bed, and other suspicious microscopic lesions. The initial planning target volume included the clinical target volume plus a 10-20 mm margin. Organs at risk were also delineated, including the spinal cord, bladder, both kidneys, and the small bowel.

The radiation dose was 45-72 Gy, with fraction sizes of 1.8-3.0 Gy (biologically equivalent dose in 2-Gy fractions \[BED~2Gy~\] using a linear quadratic model, and the α/β; ratio was 10 for acute effects on normal tissues and tumors: 44.3-74.4 BED~2Gy~), and the median dose was 57.2 BED~2Gy~. The dose-fractionation schedules were as follows: 1.8 Gy/fraction in 60 patients, 2.4 Gy/fraction in four patients, 2.7 Gy/fraction in one patient, 2.8 Gy/fraction in one patient, and a 3 Gy/fraction in one patient. The radiation dose was adjusted according to the status of the residual tumor, radiation history, and proximity to the small bowel.

Most patients underwent concurrent chemotherapy with radiation, consisting of a fluoropyrimidine (*n*= 35), irinotecan, or oxaliplatin-based regimens (*n*= 31). Only one patient could not receive chemotherapy, because of hepatitis. Maintenance chemotherapy after concurrent CRT was applied to 88.1% of patients (*n*= 59), which consisted of a fluoropyrimidine regimen (*n*= 23) and an irinotecan or oxaliplatin-based regimen (*n*= 36). The remaining eight patients did not undergo maintenance chemotherapy because of patient refusal (*n*= 6) or poor performance status (*n*= 2).

Evaluation
----------

After salvage treatment, follow-up was performed every 3 months for the first 2 post-treatment years and every 6 months thereafter. Follow-up evaluations included a physical examination, digital rectal examination, complete blood count, liver function test, and serum CEA level at each visit. Chest radiography and CT scanning of the abdomen and pelvis were performed every 6 months after salvage treatment. Relapse after salvage treatment was confirmed pathologically by direct biopsy or cytology, and/or radiographical evidence. Locoregional failure was defined as a new lesion or disease progression within the pelvic cavity, and distant failure as any recurrence outside the pelvic cavity.

Statistical Analyses
--------------------

Overall survival (OS), relapse-free survival (RFS), locoregional relapse-free survival (LRFS), and distant metastasis-free survival (DMFS) were calculated as the interval from the first date of salvage treatment to the date of death, any relapse detection, locoregional relapse detection, or distant metastasis detection, respectively.

Survival curves were generated by the Kaplan-Meier method, and a univariate survival comparison was performed using the log-rank test. Multivariate analyses were conducted with the Cox proportional hazards model and the backward stepwise selection procedure. The chi-squared, Fisher\'s exact, and *t*-tests were performed to compare various parameters between different treatment groups. A p-value of \<  0.05 was considered to indicate statistical significance.

Results
=======

Survival and pattern of failure
-------------------------------

The median follow-up time for living patients was 41 months (range, 16-108). The median OS of all patients was 59 months. Median RFS, LRFS, and DMFS were 18, not reached, and 23 months, respectively. Five-year OS, RFS, LRFS, and DMFS were 48.9%, 31.6%, 66.4%, and 40.6%, respectively. A relapse after salvage treatment occurred in 41 (61.2%) patients during the follow-up period, and locoregional failure was detected in six patients (9.0%), distant metastasis in 30 patients (44.8%), and both failures in five patients (7.5%). During follow-up period, severe G-I complication over Grade III, associated with CRT, did not occur.

Analysis of prognostic factors
------------------------------

The univariate analysis of the effect of prognostic factors on clinical outcome is shown in Table [2](#T2){ref-type="table"}. The presence of symptoms was a significant prognostic factor correlated with poor OS (p = 0.025), RFS (p = 0.007), LRFS (p = 0.003), and DMFS (p = 0.047). In contrast, age, gender, type of primary surgery, recurrence-free interval, recurrence history, recurrence site, pre-treatment CEA serum level, salvage treatment, chemotherapy regimen, resection margin, and radiation dose had no statistically significant effect on OS, RFS, LFS, or DMFS. In the multivariate analysis, the presence of symptoms was an independent prognostic factor predicting poor OS (p = 0.025; hazard ratio \[HR\], 3.46; 95% confidence interval \[CI\], 1.17-10.22), RFS (p = 0.017; HR, 3.04; 95% CI, 1.22-7.59), LRFS (p = 0.005; HR, 3.60; 95% CI, 1.48-8.80), and DMFS (p = 0.032; HR, 2.93; 95% CI, 1.10-7.89).

###### 

Univariate analysis of factors affecting clinical outcome

                                      5y OS   p†     5y RFS   p†     5y LRFS   p†     5y DMFS   p†
  ----------------------------------- ------- ------ -------- ------ --------- ------ --------- ------
  Age (years)                                                                                   
   \< 60                              50.5    .653   27.6     .547   57.6      .084             
   ≥60                                47.9           36.2            75.9                       
  Gender                                                                                        
   Male                               55.6    .381   34.8     .340   73.7      .141   42.3      .811
   Female                             34.9           27.7            55.7             38.1      
  Recurrence-free interval (months)                                                             
   \<24                               46.4    .675   33.2     .473   59.8      .248   40.6      .663
   ≥24                                50.7           26.9            72.9             38.5      
  Previous recurrence history                                                                   
   0                                  51.2    .417   36.4     .061   66.9      .834   43.0      .420
   1                                  38.8           16.7            65.2             33.0      
  Symptoms at recurrence                                                                        
   Yes                                26.3    .025   20.0     .007   40.0      .003   25.8      .047
   No                                 58.4           38.3            76.2             47.2      
  Recurrence site                                                                               
   Central                            56.0    .494   43.5     .429   67.7      .918   54.2      .305
   Lateral                            44.8           26.0            69.1             31.5      
   posterior                          36.4           35.3            63.5             36.2      
  Pretreatment CEA (ng/mL)                                                                      
   ≤5                                 45.7    .882   41.8     .071   72.1      .154   49.2      .458
   \>5                                52.8           21.8            59.1             33.8      
  Salvage Treatment                                                                             
   Surgery + CRT                      52.8    .181   35.2     .113   71.0      .379   43.6      .335
   CRT alone                          40.6           24.5            55.9             34.6      
  Chemotherapy regimen                                                                          
   Fluoropyrimidines-alone            47.3    .910   36.7     .572   67.2      .720   42.9      .562
   Irinotecan or Oxaliplatin -based   41.0           22.0            64.7             33.8      
  Resection§                                                                                    
   R0                                 60.4    .994   35.1     .956   77.7      .529   37.6      .919
   R1 or R2                           42.9           34.3            65.6             46.8      
  Radiation dose (BED~2Gy~)                                                                     
   \<60                               46.9    .607   32.3     .281   78.2      .065   41.0      .694
   ≥60                                48.3           29.2            52.9             39.2      

\*values are percentages of patients; †log rank test. OS, overall survival; **§**Among 45 patients undergoing surgical resection; RFS, recurrence-free survival; LRFS, locoregional relapse free survival; DMFS, distant metastasis-free survival; CRT, chemoradiotherapy; R0, microscopically radical; R1, microscopically irradical; R2, macroscopically irradical; BED~2Gy~, biologically equivalent dose in 2-Gy fractions using a linear quadratic model, and the α/β ratio was 10 for acute effects on normal tissues and tumors. CEA, carcinoembryonic antigen.

Comparison between CRT with and without surgery
-----------------------------------------------

No statistically significant difference was found in OS (p = 0.181), RFS (p = 0.113), LRFS (p = 0.379), or DMFS (p = 0.458) when clinical outcomes were compared between the CRT with surgery and definitive CRT without surgery groups. Figure [1](#F1){ref-type="fig"} shows the OS and RFS curves for each group. The prognostic factors, as described above, were stratified by the two groups and are shown in Table [3](#T3){ref-type="table"}. Significantly more patients with symptoms and an abnormal CEA level (\> 5 ng/mL) received definitive CRT without surgery (p = 0.014, 0.009, respectively). The mean radiation dose was 54.6 BED~2Gy~in the CRT with surgery group, and 66.5 BED~2Gy~in the definitive CRT without surgery group (p \< 0.001). In addition, post-operative RT dose was also different according to margins status. Patients with a positive resection margin received the higher radiation dose (mean dose, 57.5 BED2Gy) than patients with a negative resection margin (mean dose, 50.6 BED2Gy).

![**Overall survival (a) and relapse-free survival (b) between the chemoradiotherapy with surgery and without surgery groups**.](1748-717X-6-51-1){#F1}

###### 

Patient characteristics between the surgery plus chemoradiation and chemoradiation alone groups

  Characteristic                     Surgery + chemoradiation (*n*= 45)   chemoradiation (*n*= 22)   P
  ---------------------------------- ------------------------------------ -------------------------- ----------
  Mean age, years                    56.7 ± 11.5                          60.0 ± 13.4                0.377§
  Gender                                                                                             
   Male                              25                                   15                         0.322†
   Female                            20                                   7                          
  Recurrence-free interval, months   35.3                                 30.0                       0.521§
  Chemotherapy history                                                                               
   Yes                               35                                   20                         0.310‡
   No                                10                                   2                          
  Radiation history                                                                                  
   Yes                               14                                   6                          0.747†
   No                                31                                   16                         
  Recurrence history                                                                                 
   0                                 35                                   16                         0.649†
   1                                 10                                   6                          
  Symptoms at recurrence                                                                             
   Yes                               9                                    11                         0.014†
   no                                36                                   11                         
  Recurrence site                                                                                    
   Central                           16                                   5                          0.440†
   Lateral                           20                                   10                         
   posterior                         9                                    7                          
  Pretreatment CEA (ng/mL)                                                                           
   ≤5                                30                                   7                          0.009†
   \>5                               15                                   15                         
  Chemotherapy regimen                                                                               
   Fluoropyrimidines alone           21                                   13                         0.249†
   Irinotecan or oxaliplatin-based   24                                   8                          
  Radiation dose (BED~2Gy~)                                                                          
   \<60                              34                                   1                          \<0.001†
   ≥60                               11                                   21                         
  Mean radiation dose, BED~2Gy~      54.6 ± 5.5                           66.5 ± 6.2                 \<0.001§

†chi-squared test; ‡ Fisher exact test; **§**t-test; BED~2Gy~, biologically equivalent dose in 2-Gy fractions using a linear quadratic model, CEA, carcinoembryonic antigen; and the α/β; ratio was 10 for acute effects on normal tissues and tumors.

Discussion
==========

This study assessed whether CRT with or without surgery was effective in patients with LRRC and identified useful prognostic factors for the clinical setting. A 5-year OS of 48.9% and a LRFS of 66.4% was achieved; this outcome was better than previous multimodal treatment reports (5-yr OS of 25-36%, LRFS of 40-50%). However, DMFS was similar to the results of previous studies and was approximately 40-50% \[[@B6]-[@B8],[@B13]-[@B15]\]. When evaluating prognostic factors, symptoms related to LRRC have a significant effect on OS, RFS, LRFS, and DMFS. Pretreatment quality of life could be related to the clinical outcomes for many kinds of cancer and could be considered a potential prognostic factor. In other studies, symptoms related to LRRC have been reported as significant prognostic factors for a poor outcome \[[@B6],[@B7],[@B13]\] and such patients are considered a low possibility for radical resection \[[@B13]\]. Hydronephrosis presenting in two patients indicated a lower chance for obtaining a negative resection margin \[[@B16]\]. LRRC symptoms are a useful and readily assessable prognostic factor in the clinical setting.

Another strength of the present study was that CRT was tailored to the individual risk of a residual tumor and the potential risk of a complication after an attempt at curative resection. The patients in the LRRC group were actually heterogeneous when considering resectability, the strongest factor affecting clinical outcome. Tumor location and the degree of local invasion affect resectability, and the posterior and lateral location, particularly including a sacral, ureteral, or iliac vessel invasion, are almost unresectable and cause marked postoperative disability \[[@B10],[@B17]\]. Many studies on multimodal LRRC treatment have attempted preoperative CRT to solve the problem of low resectability \[[@B6]-[@B9],[@B13],[@B18]-[@B20]\], and one of those studies demonstrated significantly increased resectability \[[@B6]\]. However, resectability improved by preoperative CRT was still insufficient, at 30-60% \[[@B6]-[@B8],[@B13],[@B15],[@B18],[@B21]\]. The remaining 40-70% of patients with incompletely resected LRRC showed disappointing local control (30% 3-year LRFS), and this insufficient local control lead to a poor survival outcome of 10-16% for the 5-year OS \[[@B6],[@B8]\]. Moreover, the pre-operative CRT radiation dose was a uniform low dose of 30-50 Gy, but did not consider the risk of an unresectable or residual tumor. When local control is the prime goal of LRRC treatment, the radiation dose or CRT plan should be determined based on such risks for local failure and complication.

All patients, except three who underwent preoperative CRT followed by radical resection, received CRT with an adjusted postoperative or definitive radiation dose, based on the risk for local failure and complication. In the preoperative evaluation, poor surgical candidates who were definitively unresectable or medically inoperable underwent definitive CRT with a high radiation dose (mean dose, 66.5 BED~2Gy~). In patients with a positive resection margin, the post-operative radiation dose (mean dose, 57.5 BED~2Gy~) was also higher than in patients with a negative resection margin (mean dose, 50.6 BED~2Gy~). Some studies have demonstrated that a higher radiation dose for patients with LRRC is correlated with better clinical outcome \[[@B6],[@B20]\]. Fifteen patients underwent omental flap transposition as a spacer, as proposed by Kim et al. \[[@B12]\] and seven patients received proton beam or helical tomotherapy to safely deliver a high dose of radiation to recurrent sites in patients who had previously undergone radiation and whose small bowel is very close to the target area. The radiation plan also focused on risky areas for local failure, referring to operative findings and pathological reports. As a result, this study showed improved local control, leading to improved OS. Moreover, patients with a positive resection margin demonstrated notably better outcomes (5-year OS, 42.9%) than other studies \[[@B6],[@B7],[@B13]\]. This study showed that the purpose of CRT should not be just adjuvant, aimed at increasing resectability, but an aggressive curative local control, similar to surgery. Such a treatment plan could result in an increased cure rate with long-term survival.

The present study also showed that definitive CRT with a high radiation dose (mean dose, 66.5 BED~2Gy~) may be a potentially curative option for long-term survival (5-year OS, 48.9%). The actuarial 5-year OS, RFS, LRFS, and DMFS for definitive CRT was not significantly different than CRT with surgery. However, median OS, RFS, LRFS, and DMFS for definitive CRT tended to be slightly inferior to the surgery group, but this difference was not statistically significant. Patients with an abnormal CEA level or the presence of symptoms occurred more in the definitive CRT group, and this may have affected the outcome of the definitive CRT group. Symptoms were a significant prognostic factor in the present study and CEA level has been reported as a significant prognostic factor in some previous studies \[[@B22],[@B23]\]. Although definitive CRT cannot substitute for radical surgery, it can be an option aimed at a cure with long-term survival for a fair number of patients with an inoperable medical condition or an unresectable lesion.

The present study has some limitations. First, in contrast to other studies, the radicality of resection was not a significant prognostic factor predicting survival outcome or tumor control. It might be related with low statistical power due to small sample size (*n*= 67). In addition, the reason could be also that radiation dose was increased according to residual tumor status. Such a difference in the radiation dose appeared to dilute the effect of surgical radicality. Another reason could be that a relatively small proportion of R2 resections (4%) of the CRT with surgery might induce improvement in the group with positive resection margin. Patients with expected unresectability from the radiological evaluation were recommended for definitive CRT without surgery, so a R2 resection might have been rarer than in other studies. In that R2 resection have more effect on an unfavorable clinical outcome than R1 resection \[[@B24]\], the effect of radicality might fail to get the statistical significance. Second, we could observe tendency in the survival curves that the CRT with surgery got the slightly more favorable outcome than the definitive CRT group, but it failed to get a statistical significance. This could be resulted from the effects of a small sample size, surgical morbidities, and the differences of radiation dose. This study showed the possibility of a definitive CRT for cure, but further study with a larger sample size is needed for a definitive conclusion about the comparison between the two groups. Third, we had a heterogeneous population undergoing different CRT approaches and chemotherapy regimens. Accordingly, further larger scale and prospective studies with additional long-term follow-up are needed to compare different CRT approaches definitively.

Conclusions
===========

Our study demonstrated that LRRC has the potential to be cured with CRT with or without surgery, and the symptoms related to LRRC are a significant prognostic factor predicting poor clinical outcome. The CRT approach should focus on local control; thus, individualized CRT strategies are recommended, based on the possibility of resectability and risk of local failure. Thus, CRT with an adjusted radiation dose is a potential curative option for LRRC, including definitive CRT without surgery.
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